Department of Clinical Oncology, Leeds Cancer Centre, Leeds, LS9 7TF, UK.
Level 4, Leeds Cancer Centre, St. James's University Hospital, Beckett St., Leeds, LS9 7TF, UK.
Eur Radiol. 2020 Feb;30(2):1212-1220. doi: 10.1007/s00330-019-06401-7. Epub 2019 Aug 29.
The limited positive predictive value of an incomplete response on PET-CT following (chemo)radiotherapy for head and neck squamous cell carcinoma (HNSCC) means that the optimal management strategy remains uncertain. The aim of the study is to assess the utility of a 'second-look' interval PET-CT.
Patients with HNSCC who were treated with (chemo)radiotherapy between 2008 and 2017 and underwent (i) baseline and (ii) response assessment PET-CT and (iii) second-look PET-CT following incomplete (positive or equivocal scan) response were included. Endpoints were conversion rate to complete response (CR) and test characteristics of the second-look PET-CT.
Five hundred sixty-two patients with HNSCC underwent response assessment PET-CT at a median of 17 weeks post-radiotherapy. Following an incomplete response on PET-CT, 40 patients underwent a second-look PET-CT at a median of 13 weeks (range 6-25) from the first response PET-CT. Thirty-four out of 40 (85%) patients had oropharyngeal carcinoma. Twenty-four out of 40 (60%) second-look PET-CT scans converted to a complete locoregional response. The primary tumour conversion rate was 15/27 (56%) and the lymph node conversion rate was 14/19 (74%). The sensitivity, specificity, positive predictive value and negative predictive value (NPV) of the second-look PET-CT were 75%, 75%, 25% and 96% for the primary tumour and 100%, 92%, 40% and 100% for lymph nodes. There were no cases of progression following conversion to CR in the primary site or lymph nodes.
The majority of patients who undergo a second-look PET-CT convert to a CR. The NPV of a second-look PET-CT is high, suggesting the potential to avoid surgical intervention.
• PET-CT is a useful tool for response assessment following (chemo)radiotherapy for head and neck squamous cell carcinoma. • An incomplete response on PET-CT has a limited positive predictive value and optimal management is uncertain. • These data show that with a 'second-look' interval PET-CT, the majority of patients convert to a complete metabolic response. When there is doubt about clinical and radiological response, a 'second-look' PET-CT can be used to spare patients unnecessary surgical intervention.
在头颈部鳞状细胞癌(HNSCC)放化疗后,PET-CT 检查不完全缓解的阳性预测值有限,这意味着最佳的管理策略仍不确定。本研究旨在评估“二次观察”间隔 PET-CT 的实用性。
纳入 2008 年至 2017 年间接受(化疗)放疗治疗的 HNSCC 患者,并进行了(i)基线和(ii)反应评估 PET-CT 和(iii)不完全(阳性或不确定扫描)反应后进行“二次观察”PET-CT。终点为完全缓解(CR)转化率和二次观察 PET-CT 的检测特征。
562 例 HNSCC 患者在放疗后中位数 17 周进行反应评估 PET-CT。在 PET-CT 检查不完全缓解后,40 例患者在首次反应 PET-CT 后中位数 13 周(范围 6-25 周)进行了二次观察 PET-CT。40 例患者中有 34 例(85%)为口咽癌。40 例患者中有 24 例(60%)的二次观察 PET-CT 转为完全局部缓解。原发肿瘤转化率为 15/27(56%),淋巴结转化率为 14/19(74%)。二次观察 PET-CT 的敏感性、特异性、阳性预测值和阴性预测值(NPV)为原发肿瘤 75%、75%、25%和 96%,淋巴结为 100%、92%、40%和 100%。在原发部位或淋巴结转为 CR 后,无进展病例。
大多数接受二次观察 PET-CT 的患者都转为 CR。二次观察 PET-CT 的 NPV 较高,提示有可能避免手术干预。
PET-CT 是头颈部鳞状细胞癌放化疗后评估反应的有用工具。
PET-CT 检查不完全缓解的阳性预测值有限,最佳治疗方案尚不确定。
这些数据表明,通过“二次观察”间隔 PET-CT,大多数患者可转为完全代谢缓解。当对临床和影像学反应有疑问时,可使用“二次观察”PET-CT 来避免不必要的手术干预。